{"version":"1.0","provider_name":"Inven2 oppsummering av 2021","provider_url":"https:\/\/annual.inven2.com\/2021","author_name":"Jannicke Kristoffersen","author_url":"https:\/\/annual.inven2.com\/2021\/author\/jannicke\/","title":"A UNIQUE BIOLOGICAL SUPER-TAXI HAS BEEN DEVELOPED - Inven2 oppsummering av 2021","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"wHG4K8rzoH\"><a href=\"https:\/\/annual.inven2.com\/2021\/en\/featured_item\/unique-biological-super-taxi\/\">A UNIQUE BIOLOGICAL SUPER-TAXI HAS BEEN DEVELOPED<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/annual.inven2.com\/2021\/en\/featured_item\/unique-biological-super-taxi\/embed\/#?secret=wHG4K8rzoH\" width=\"600\" height=\"338\" title=\"&laquo;A UNIQUE BIOLOGICAL SUPER-TAXI HAS BEEN DEVELOPED&raquo; &#8212; Inven2 oppsummering av 2021\" data-secret=\"wHG4K8rzoH\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/annual.inven2.com\/2021\/wp-content\/uploads\/2018\/12\/IMG_0143_web.jpg","thumbnail_width":1200,"thumbnail_height":675,"description":"This article was first published on Inven2's website on 15 October 2020.  Since then, a small part of the super albumin platform technology has been licensed to an international company. Both Inven2 and the researchers have also received milestone funding for commercial development work from the Research Council of Norway for other applications of the platform technology.   Inven2 would like to get in touch with industry players for the licensing of different areas of application for the technology. If you would like more information, please contact Gerbrand Koster Technology Strategy Manager at Inven2."}